RT @doctorRBC: Risankizumab (IL-23i) phase III trial for PsA inadequate response to biologic âï¸ACR20, 50,70 response
Tweet Content
Risankizumab (IL-23i) phase III trial for PsA inadequate response to biologic
⭐️ACR20, 50,70 response
⭐️significant resolution of enthesitis/dactylitis
Abs#OP0228
#EULAR2021 @RheumNow
Show on Archive Page
On
Display in Search Results
On
PDQ
Off